Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

Inclusion Criteria: * Patients aged ≥ 18 years * Vasoplegic shock defined as patient requiring vasopressor at the time of inclusion AND with a cardiac index ≥ 2.3/L/min/m² \[32\] (measured by echocardiography, Swan-Ganz, pulse contour analysis or thermodilution) and with hyperlactatemia \> 2 mmol/l. * Vasoplegia must be primarily caused by one of the following etiologies: * Sepsis (documented or clinically suspected infection) * Post-operative vasoplegia (following cardiac or non-cardiac surgery) * Post hemorrhage * Sterile systemic inflammation (e.g., pancreatitis, burns, trauma) * Anaphylaxis * Liver failure * Other causes of vasoplegia * Refractory shock: dose of vasopressor (express as norepinephrine base equivalent) ≥ 0.25 μg/kg/min in order to maintain perfusion pressure within patient-defined targets (defined by the physician in charge of the patient). * Early intervention: Criteria for refractory AND vasoplegic shock reached for less than 12 hours. * Informed consent obtained from the patient or, if unable to give consent, a surrogate. If the surrogate is not available, emergency consent can be considered. * Covered by French national health insurance Exclusion Criteria: * Patients that do not present the criteria for vasoplegic AND refractory shock at the time of inclusion anymore (resolved condition) * Ongoing vasopressin treatment * Ongoing inotrope treatment (except norepinephrine) * Ongoing acute coronary syndrome, mesenteric ischemia * Uncontrolled active bleeding * Vasoplegia due to neurogenic shock * Vasospastic disease (Raynaud's disease, systemic scleroderma…) * Hyponatremia \<120 mmol l-1 * Known hypersensitivity to Argipressin or to any of the excipients of REVERPLEG®. * Patient already enrolled in an interventional trial * Decision to limit life-sustaining treatments * Person under legal protection * Pregnant, parturient or breastfeeding women